**Results**

# Dexamethasone-Induced Insulin Resistance is Worsened in the Presence of Obesity

Our group has previously published data () that illustrates different physiological and gene expression outcomes between those with Cushing’s disease (ACTH-secreting pituitary adenoma) and controls (non-secreting pituitary adenoma). More recently, we speculated that the conditions within the groups may vary according to obesity status. Here we have re-analyzed the data stratifying the Cushingoid and control groups by BMI, classifying these individuals as “Not obese” (BMI < 30) and “Obese” (BMI ≥ 30). The presence of Cushing’s in individuals with a high BMI leads to increased insulin resistance (measured by HOMA-IR score), above that of Cushing’s or obesity alone. However, it is not possible to determine when these individuals developed this disease and what their weight status was prior to their diagnosis.

To further investigate if obesity status influences insulin sensitivity in the presence of high glucocorticoids we performed an insulin tolerance test (ITT) on lean (NCD) and diet-induced obese (HFD) mice that were untreated (Control) or treated with glucocorticoids (Dexamethasone; Figure 1A-B--schematic). All groups were given a relatively large dose of insulin (2.5 U/kg) to account for the known insulin resistance typically seen in diet-induced obese (cite). HFD-fed, dexamethasone-treated mice were significantly more resistant to insulin-stimulated glucose uptake when compared to all other groups. Though, it is important to note that the NCD-fed, dexamethasone treated animals still experienced some insulin resistance at this high dose. Additionally, these mice were hyperglycemic, a condition not seen when mice are treated with dexamethasone or HFD alone.

Clamp data

# HFD-Induced Liver Steatosis is Worsened in Dexamethasone Treated mice

Obesity and chronic elevations in glucocorticoids have been associated with increased liver fat and even non-alcoholic fatty liver disease (NAFLD). We observed slight increases in plasma AST and ALT, which are liver enzymes associated with liver disease (cite?), in Cushing’s patients and obese controls; interestingly, levels were further elevated in obese Cushing’s patients, synergistically so in the case of ALT.

Since elevated liver enzymes are just one indicator of liver disease, they are not sufficient to lend a diagnosis, we studied this in our mouse model. HFD-fed, Dexamethasone treated mice had significantly elevated liver triglycerides when compared to all other groups (Figure). In support of this, H&E staining of hepatic tissue clearly depicts higher lipid levels in this group (Figure). Collagen/trichrome data…

Expression of genes involved hepatic *de novo* lipogenesis (*Srebf1* and *Fasn*) was assessed via qPCR (Figure). Both transcripts were highly elevated in response to HFD alone; however, levels were found to be comparable among all other groups. This finding indicates that lipid accumulation resulting from dexamethasone treatment is occurring via a different mechanism than that which occurs as a result of diet-induced obesity.

# Dexamethasone Causes Decreased Fat Mass in HFD-Fed Mice

Dexamethasone treatment lead to decreased body mass in both NCD and HFD groups (FIG). The reduced body mass was primarily due to lean mass loss. Surprisingly, there was also a loss in fat mass in the HFD-fed, dexamethasone treated group (Figs-- MRI and fat pad weights). There were no significant differences in food consumption.

Fat cell size/inflammation…

Dexamethasone Treatment Results in Increased Lipolysis

Lipolysis has previously been associated with insulin resistance, is a known cause of Non-Alcoholic Fatty Liver Disease (NAFLD; cite), and has been shown to increase with glucocorticoid treatment. We first assessed whether there was a direct effect of dexamethasone on adipocytes in culture (figures). 3T3-L1 fibroblasts were either kept in media alone (pre-adipocytes), differentiated (mature adipocytes) or treated with dexamethasone following differentiation (mature adipocytes +dexamethasone) over a 15-day period. Dexamethasone treatment following differentiation lead to decreased lipid content and increased glycerol release into the media, indicating increased lipolysis. To assess this further, we measured lipolytic enzyme mRNA and protein expression levels in these cells (figure). Expression of ATGL (encoded by *Pnpla2*) and HSL (encoded by *Lipe*) were enhanced following dexamethasone treatment.

To assess the effects of glucocorticoid-induced lipolysis *in vivo,* we measured the by-products of triglyceride breakdown, glycerol and free fatty acids in basal and stimulated conditions (figure). Stimulation of lipolysis was achieved via isoproterenol, a -adrenergic receptor agonist, or by a 16-hour fast. For isoproterenol stimulation of lipolysis fed mice were i.p. injected with 10 mg/kg isoproterenol and basal levels were determined prior to injections. Serum free fatty acids and glycerol were measured for each of these conditions. Dexamethasone treatment led to increases in glycerol and free fatty acids across all conditions.

qPCR lipolytic genes in these mice

These data show that glucocorticoids directly stimulate lipolysis in adipose tissue.

# Dexamethasone-Induced Lipolysis is increased in HFD-Fed Mice

To determine whether the effect of dexamethasone-induced in vivo lipolysis was exacerbated in the context of obesity we measured serum glycerol following a 16-hour fast (figure). Similarly, was elevated in dexamethasone treated animals and there was a significant interaction between drug and diet (p value).

We also quantified mRNA and protein expression of lipolytic enzymes, ATGL and HSL, in the iWAT of these mice. Consistent with the above findings, expression was elevated in the dexamethasone-treated groups and there was a significant interaction of drug and diet. These data show that glucocorticoid-stimulated lipolysis is augmented in the context of obesity.